Ellis C N, Goldfarb M T, Roenigk H H, Rosenbaum M, Wheeler S, Voorhees J J
J Am Acad Dermatol. 1986 Jan;14(1):49-52. doi: 10.1016/s0190-9622(86)70006-6.
One hundred three patients entered a study to evaluate the effects of oral meclofenamate sodium therapy on psoriasis. The first 4 weeks of the study were double-blind, with patients receiving either meclofenamate or placebo. Most patients receiving meclofenamate had no change in their psoriasis, in comparison with their pretherapy condition. There was no difference in the response of the psoriasis between the group taking meclofenamate and the group taking placebo. Eighty-nine patients continued in a 4-week open trial of meclofenamate. Approximately one third of the patients showed improvement, but this result appeared to be related to the open trial design. Since oral meclofenamate therapy was not associated with frequent worsening of psoriasis, it is an appropriate treatment for psoriatic arthritis.
103名患者参与了一项评估口服甲氯芬那酸钠疗法对银屑病疗效的研究。研究的前4周为双盲期，患者分别接受甲氯芬那酸或安慰剂治疗。与治疗前相比，大多数接受甲氯芬那酸治疗的患者银屑病病情无变化。服用甲氯芬那酸的组和服用安慰剂的组在银屑病反应上没有差异。89名患者继续进行了为期4周的甲氯芬那酸开放试验。约三分之一的患者病情有所改善，但这一结果似乎与开放试验设计有关。由于口服甲氯芬那酸疗法不会频繁导致银屑病病情恶化，因此它是银屑病关节炎的一种合适治疗方法。
